{"protocolSection": {"identificationModule": {"nctId": "NCT00337675", "orgStudyIdInfo": {"id": "0476-302"}, "secondaryIdInfos": [{"id": "MK0476-302"}, {"id": "2006_015"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)", "officialTitle": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-10"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-06-14", "studyFirstSubmitQcDate": "2006-06-14", "studyFirstPostDateStruct": {"date": "2006-06-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-02-19", "resultsFirstSubmitQcDate": "2010-02-19", "resultsFirstPostDateStruct": {"date": "2010-03-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1771, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1: drug + episodic supplemental placebo", "type": "ACTIVE_COMPARATOR", "description": "Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "Arm 2: placebo comparator + episodic supplemental drug", "type": "ACTIVE_COMPARATOR", "description": "Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "Arm 3: placebo comparator + episodic supplemental placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period", "interventionNames": ["Drug: Comparator: Placebo (unspecified)"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.", "armGroupLabels": ["Arm 1: drug + episodic supplemental placebo"], "otherNames": ["MK0476", "Singulair\u00ae"]}, {"type": "DRUG", "name": "Comparator: Placebo (unspecified)", "description": "Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.", "armGroupLabels": ["Arm 3: placebo comparator + episodic supplemental placebo"]}, {"type": "DRUG", "name": "montelukast sodium", "description": "Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.", "armGroupLabels": ["Arm 2: placebo comparator + episodic supplemental drug"], "otherNames": ["MK0476", "Singulair\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period", "description": "The rate per year of asthma episodes culminating in an asthma attack for each of the 3 treatment groups. Asthma attacks were defined as respiratory symptoms requiring healthcare resource utilization (HRU), which comprised unscheduled visits to a physician or emergency department, treatment with corticosteroids (oral, rectal, or inhaled), or hospitalization. Each day during an episode, the patient's legal guardian recorded all the HRU that was required specifically for breathing problems.", "timeFrame": "1-year treatment period"}], "secondaryOutcomes": [{"measure": "Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode", "description": "Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of wheeze and difficulty breathing on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 3 days prior to an asthma attack was reported. If a patient had multiple episodes during 1 year, the symptom scores were averaged across all the episodes.", "timeFrame": "1 Year"}, {"measure": "Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes", "description": "Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of Wheeze, Difficulty Breathing, Interference with Activity, and Daytime Cough on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 12 days of intermittent treatment for an episode (before the first attack) was reported. If a patient had multiple episodes over 1 year, the symptom scores were averaged across all the episodes.", "timeFrame": "1 Year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged 6 months to 5 years with episodic (periodic) asthma\n\nExclusion Criteria:\n\n* Patients who are not in otherwise good health\n* Patients who have persistent asthma (continual asthma symptoms)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Months", "maximumAge": "5 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21624752", "type": "RESULT", "citation": "Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "1979 screened; 208 excluded.\n\nRandomized patients met the following criteria: age 6-71 months, a history of episodic asthma symptoms that ranged between 2 and 6 episodes, depending on age, that were separated in time by periods without asthma symptoms. Patients had at least 1 corticosteroid treatment or were hospitalized for asthma at least 1 time.", "recruitmentDetails": "Patients were recruited from 111 centers worldwide.\n\nPatient screening began 16-Oct-2006 and the first patient was randomized on 3-Nov-2006.\n\nThe last patient's last visit was completed on 12-Aug-2009.", "groups": [{"id": "FG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "FG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "FG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "589"}, {"groupId": "FG001", "numSubjects": "591"}, {"groupId": "FG002", "numSubjects": "591"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "492"}, {"groupId": "FG001", "numSubjects": "488"}, {"groupId": "FG002", "numSubjects": "492"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "103"}, {"groupId": "FG002", "numSubjects": "99"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "Progressive Disease", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Trial Terminated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "BG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "BG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "589"}, {"groupId": "BG001", "value": "591"}, {"groupId": "BG002", "value": "591"}, {"groupId": "BG003", "value": "1771"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.0", "lowerLimit": "6.0", "upperLimit": "71.0"}, {"groupId": "BG001", "value": "39.5", "lowerLimit": "6.0", "upperLimit": "71.0"}, {"groupId": "BG002", "value": "39.3", "lowerLimit": "7.0", "upperLimit": "71.0"}, {"groupId": "BG003", "value": "39.2", "lowerLimit": "6.0", "upperLimit": "71.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "239"}, {"groupId": "BG001", "value": "226"}, {"groupId": "BG002", "value": "238"}, {"groupId": "BG003", "value": "703"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "350"}, {"groupId": "BG001", "value": "365"}, {"groupId": "BG002", "value": "353"}, {"groupId": "BG003", "value": "1068"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period", "description": "The rate per year of asthma episodes culminating in an asthma attack for each of the 3 treatment groups. Asthma attacks were defined as respiratory symptoms requiring healthcare resource utilization (HRU), which comprised unscheduled visits to a physician or emergency department, treatment with corticosteroids (oral, rectal, or inhaled), or hospitalization. Each day during an episode, the patient's legal guardian recorded all the HRU that was required specifically for breathing problems.", "populationDescription": "Full Analysis Set (FAS): all randomized patients who took at least one dose of blinded study drug. Of 1771 patients randomized, 5 never took study drug and 9 were not included due to Good Clinical Practice compliance concerns. Therefore, 1757 patients were included in the FAS population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Asthma attacks within episodes per year", "timeFrame": "1-year treatment period", "groups": [{"id": "OG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "584"}, {"groupId": "OG001", "value": "588"}, {"groupId": "OG002", "value": "585"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "lowerLimit": "0.86", "upperLimit": "1.14"}, {"groupId": "OG001", "value": "1.06", "lowerLimit": "0.92", "upperLimit": "1.22"}, {"groupId": "OG002", "value": "1.05", "lowerLimit": "0.92", "upperLimit": "1.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "The primary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in a decrease in the number of asthma episodes culminating in asthma attack in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year. A sample size of 450 evaluable patients per arm allowed the detection of a difference in rate of 23% with 90% power.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.510", "pValueComment": "Multiplicity adjustment across regimens was addressed through step-down testing. Daily montelukast versus placebo was tested first; if this comparison was significant, intermittent montelukast versus placebo was tested. The significance level was 5%.", "statisticalMethod": "Regression, Poisson", "statisticalComment": "A Poisson regression model containing factors for treatment, age group, and geographic region, and an offset for number of days in study was used.", "paramType": "Rate reduction", "paramValue": "5.3", "ciPctValue": "95", "ciLowerLimit": "-11.4", "ciUpperLimit": "19.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.3", "estimateComment": "Rate reduction = (1 - montelukast-adjusted annual rate/placebo-adjusted annual rate) x 100%"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "The primary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in a decrease in the number of asthma episodes culminating in asthma attack in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year. A sample size of 450 evaluable patients per arm allowed the detection of a difference in rate of 23% with 90% power.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.884", "pValueComment": "Multiplicity adjustment across regimens was addressed through step-down testing. Daily montelukast versus placebo was tested first; if this comparison was significant, intermittent montelukast versus placebo was tested. The significance level was 5%.", "statisticalMethod": "Regression, Poisson", "statisticalComment": "A Poisson regression model containing factors for treatment, age group, and geographic region, and an offset for number of days in study was used.", "paramType": "Rate reduction", "paramValue": "-1.2", "ciPctValue": "95", "ciLowerLimit": "-19.2", "ciUpperLimit": "14.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.8", "estimateComment": "Rate reduction = (1 - montelukast-adjusted annual rate/placebo-adjusted annual rate) x 100%"}]}, {"type": "SECONDARY", "title": "Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode", "description": "Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of wheeze and difficulty breathing on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 3 days prior to an asthma attack was reported. If a patient had multiple episodes during 1 year, the symptom scores were averaged across all the episodes.", "populationDescription": "Only patients who experienced an asthma attack within an episode and did not start their intermittent study medication on the day of the attack could be included. Therefore, a total of 452 patients were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "1 Year", "groups": [{"id": "OG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.69", "lowerLimit": "1.49", "upperLimit": "1.88"}, {"groupId": "OG001", "value": "1.70", "lowerLimit": "1.52", "upperLimit": "1.89"}, {"groupId": "OG002", "value": "1.88", "lowerLimit": "1.69", "upperLimit": "2.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "The secondary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.176", "pValueComment": "Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the 2 endpoints assessing severity, adjustment for multiplicity was performed using Hochberg's method.", "statisticalMethod": "ANOVA", "statisticalComment": "An ANOVA model containing factors for treatment, age group, and geographical region was used.", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.19", "ciPctValue": "95", "ciLowerLimit": "-0.46", "ciUpperLimit": "0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.14"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "The secondary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.202", "pValueComment": "Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the 2 endpoints assessing severity, adjustment for multiplicity was performed using Hochberg's method.", "statisticalMethod": "ANOVA", "statisticalComment": "An ANOVA model containing factors for treatment, age group, and geographical region was used.", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.17", "ciPctValue": "95", "ciLowerLimit": "-0.44", "ciUpperLimit": "0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.14"}]}, {"type": "SECONDARY", "title": "Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes", "description": "Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of Wheeze, Difficulty Breathing, Interference with Activity, and Daytime Cough on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 12 days of intermittent treatment for an episode (before the first attack) was reported. If a patient had multiple episodes over 1 year, the symptom scores were averaged across all the episodes.", "populationDescription": "Patients with at least one episode culminating in an attack were included; therefore, 1120 patients were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "1 Year", "groups": [{"id": "OG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}, {"id": "OG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "365"}, {"groupId": "OG001", "value": "387"}, {"groupId": "OG002", "value": "368"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.08", "lowerLimit": "1.00", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "1.09", "lowerLimit": "1.01", "upperLimit": "1.17"}, {"groupId": "OG002", "value": "1.20", "lowerLimit": "1.12", "upperLimit": "1.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "The secondary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.045", "pValueComment": "Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the family of secondary endpoints, adjustment for multiplicity was performed using Hochberg's method.", "statisticalMethod": "ANOVA", "statisticalComment": "An ANOVA model containing factors for treatment, age group, and geographical region was used.", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.12", "ciPctValue": "95", "ciLowerLimit": "-0.24", "ciUpperLimit": "0.00", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.06"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "The secondary hypothesis stated that montelukast (daily regimen, or \\[intermittent and daily regimens\\]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.061", "pValueComment": "Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the family of secondary endpoints, adjustment for multiplicity was performed using Hochberg's method.", "statisticalMethod": "ANOVA", "statisticalComment": "An ANOVA model containing factors for treatment, age group, and geographical region was used.", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.11", "ciPctValue": "95", "ciLowerLimit": "-0.23", "ciUpperLimit": "0.00", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.06"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "October 2006 through August 2009", "eventGroups": [{"id": "EG000", "title": "Daily Montelukast", "description": "Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.", "seriousNumAffected": 28, "seriousNumAtRisk": 584, "otherNumAffected": 481, "otherNumAtRisk": 584}, {"id": "EG001", "title": "Intermittent Montelukast", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.", "seriousNumAffected": 41, "seriousNumAtRisk": 588, "otherNumAffected": 506, "otherNumAtRisk": 588}, {"id": "EG002", "title": "Placebo", "description": "Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.", "seriousNumAffected": 33, "seriousNumAtRisk": 585, "otherNumAffected": 486, "otherNumAtRisk": 585}], "seriousEvents": [{"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Hydrocele", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Peritonitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Adenoiditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Adenovirus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Bronchiolitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 585}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Croup infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Encephalitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Hand-foot-and-mouth disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Hepatitis A", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Hepatitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Kawasaki's disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Laryngotracheitis obstructive", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Lower respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Lower respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Parotid abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 585}]}, {"term": "Pneumonia mycoplasmal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Pneumonia primary atypical", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Pneumonia viral", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Tracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Viral diarrhoea", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Viral rash", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Accidental poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Synovitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Febrile convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 585}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 585}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 585}]}, {"term": "Stridor", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 585}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 49, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 43, "numAtRisk": 585}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 30, "numAtRisk": 585}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 94, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 87, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 80, "numAtRisk": 585}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 40, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 585}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 585}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 110, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 110, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 81, "numAtRisk": 585}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 44, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 55, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 45, "numAtRisk": 585}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 59, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 64, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 67, "numAtRisk": 585}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 30, "numAtRisk": 585}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 49, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 585}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 42, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 37, "numAtRisk": 585}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 81, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 76, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 82, "numAtRisk": 585}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 28, "numAtRisk": 585}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 332, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 338, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 319, "numAtRisk": 585}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 91, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 101, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 93, "numAtRisk": 585}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 31, "numAtRisk": 585}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 585}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 584}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 588}, {"groupId": "EG002", "numAffected": 37, "numAtRisk": 585}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Brazil", "Canada", "Chile", "Colombia", "Costa Rica", "Denmark", "Finland", "France", "Germany", "Guatemala", "Israel", "Italy", "Lithuania", "Mexico", "Peru", "Russian Federation", "Singapore", "South Africa", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}